1. bookVolume 68 (2018): Issue 2 (June 2018)
Journal Details
License
Format
Journal
eISSN
1846-9558
First Published
28 Feb 2007
Publication timeframe
4 times per year
Languages
English
access type Open Access

Paeoniflorin inhibits the growth of bladder carcinoma via deactivation of STAT3

Published Online: 26 Apr 2018
Page range: 211 - 222
Accepted: 20 Dec 2017
Journal Details
License
Format
Journal
eISSN
1846-9558
First Published
28 Feb 2007
Publication timeframe
4 times per year
Languages
English
Abstract

Bladder cancer (BCa) is one of the most common urinary cancers. The present study aims to investigate whether Paeoniflorin (Pae) can exert inhibitory effects on BCa. The results showed that Pae inhibited proliferation of human BCa cell lines in a concentration- and time-dependent manner. Pae and cisplatin (Cis) synergistically inhibited the growth of tumours in RT4-bearing mice. Pae treatment neutralized the body loss induced by Cis. Moreover, Pae induced apoptosis in RT4 cells and increased the activities of caspase3, caspase8 and caspase9. Western blotting and immunohistochemical analysis revealed that the phosphorylated signal transducer and activator of transcription-3 (p-STAT3) level were decreased in Pae-treated RT4 cells and Pae-treated tumour-bearing mice. Furthermore, STAT3 transcriptional target B-cell lymphoma-2 was decreased in Pae-treated RT4 cells. Interestingly, Pae prevented translocation of STAT3 to the nucleus in RT4 cells. Collectively, Pae inhibits the growth of BCa, at least in part, via a STAT3 pathway.

Keywords

1. M. Peng, Y. Huang, T. Tao, C. Y. Peng, Q. Su, W. Xu, K. O. Darko, X. Tao and X. Yang, Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk, Sci. Rep. 6 (2016) 28611; https://doi.org/10.1038/srep2861110.1038/srep28611491787127334428Search in Google Scholar

2. R. Arantes-Rodrigues, R. Pinto-Leite, L. Fidalgo-Gonçalves, C. Palmeira, L. Santos, A. Colaço and P. Oliveira, Synergistic effect between cisplatin and sunitinib malate on human urinary bladder-cancer cell lines, Biomed. Res. Int. (2013) 791406; https://doi.org/10.1155/2013/79140610.1155/2013/791406386348324369536Search in Google Scholar

3. E. W. Gerharz, A. Månsson and W. Månsson, Quality of life in patients with bladder cancer, Urol. Oncol.23 (2005) 201–207; https://doi.org/10.1016/j.urolonc.2005.03.00510.1016/j.urolonc.2005.03.00515907722Search in Google Scholar

4. E. J. Hillmer, H. Zhang, H. S. Li and S. S. Watowich, STAT3 signaling in immunity, Cytokine Growth Factor Rev.31 (2016) 1–15; https://doi.org/10.1016/j.cytogfr.2016.05.00110.1016/j.cytogfr.2016.05.001505009327185365Search in Google Scholar

5. S. Bhattacharya, R. M. Ray and L. R. Johnson, STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells, Biochem. J. 392 (2005) 335–344; https://doi.org/10.1042/BJ2005046510.1042/BJ20050465131626916048438Search in Google Scholar

6. J. Bromberg and J. E. Jr. Darnell, The role of STATs in transcriptional control and their impact on cellular function, Oncogene19 (2000) 2468–2473; https://doi.org/10.1038/sj.onc.120347610.1038/sj.onc.120347610851045Search in Google Scholar

7. M. Degoricija, M. Situm, J. Korać, A. Miljković, K. Matić, M. Paradžik, I. Marinović Terzić, A. Jerončić, S. Tomić and J. Terzić, High NF-κB and STAT3 activity in human urothelial carcinoma: a pilot study, World. J. Urol. 32 (2014) 1469–1475; https://doi.org/10.1007/s00345-014-1237-110.1007/s00345-014-1237-124448750Search in Google Scholar

8. B. Zhang, Z. Lu, Y. Hou, J. Hu and C. Wang, The effects of STAT3 and Survivin silencing on the growth of human bladder carcinoma cells, Tumour Biol.35 (2014) 5401–5407; https://doi.org/10.1007/s13277-014-1704-810.1007/s13277-014-1704-824519067Search in Google Scholar

9. H. H. Yeh, R. Giri, T. Y. Chang, C. Y. Chou, W. C. Su and H. S. Liu, Ha-ras oncogene-induced Stat3 phosphorylation enhances oncogenicity of the cell, DNA. Cell. Biol.28 (2009) 131–139; https://doi.org/10.1089/dna.2008.076210.1089/dna.2008.076219182994Search in Google Scholar

10. R. J. Chen, Y. S. Ho, H. R. Guo and Y. J. Wang, Long-term nicotine exposure-induced chemoresistance is mediated by activation of Stat3 and downregulation of ERK1/2 via nAChR and beta- adrenoceptors in human bladder cancer cells, Toxicol. Sci.115 (2010) 118–130; https://doi.org/10.1093/toxsci/kfq02810.1093/toxsci/kfq02820106947Search in Google Scholar

11. S. Parker, B. May, C. Zhang, A. L. Zhang, C. Lu and C. C. Xue, A pharmacological review of bioactive constituents of Paeonia lactiflora Pallas and Paeonia veitchii Lynch, Phytother. Res.30 (2016) 1445–1473; https://doi.org/10.1002/ptr.565310.1002/ptr.565327279421Search in Google Scholar

12. J. Hao, X. Yang, X. L. Ding, L. M. Guo, C. H. Zhu, W. Ji, T. Zhou and X. Z. Wu, Paeoniflorin potentiates the inhibitory effects of erlotinib in pancreatic cancer cell lines by reducing ErbB3 phosphorylation, Sci. Rep.6 (2016) 32809; https://doi.org/10.1038/srep3280910.1038/srep32809501685127609096Search in Google Scholar

13. X. H. Nie, J. Ou-yang, Y. Xing, D. Y. Li, X. Y. Dong, R. E. Liu and R. X. Xu, Paeoniflorin inhibits human glioma cells via STAT3 degradation by the ubiquitin-proteasome pathway, Drug. Des. Devel. Ther.9 (2015) 5611–5622; https://doi.org/10.2147/DDDT.S9391210.2147/DDDT.S93912461077926508835Search in Google Scholar

14. H. Wang, H. Zhou, C. X. Wang, Y. S. Li, H. Y. Xie, J. D. Luo and Y. Zhou, Paeoniflorin inhibits growth of human colorectal carcinoma HT 29 cells in vitro and in vivo, Food Chem. Toxicol.50 (2012) 1560–1567; https://doi.org/10.1016/j.fct.2012.01.03510.1016/j.fct.2012.01.03522326807Search in Google Scholar

15. Y. B. Zheng, G. C. Xiao, S. L. Tong, Y. Ding, Q. S. Wang, S. B. Li and Z. N. Hao, Paeoniflorin inhibits human gastric carcinoma cell proliferation through up-regulation of microRNA-124 and suppression of PI3K/Akt and STAT3 signaling, World J. Gastroenterol.21 (2015) 7197–7207; https://doi.org/10.3748/wjg.v21.i23.719710.3748/wjg.v21.i23.7197447688126109806Search in Google Scholar

16. M. Y. Lin, S. Y. Chiang, Y. Z. Li, M. F. Chen, Y. S. Chen, J. Y. Wu and Y. W. Liu, Anti-tumor effect of Radix Paeoniae rubra extract on mice bladder tumors using intravesical therapy, Oncol. Lett.12 (2016) 904–910; https://doi.org/10.3892/ol.2016.469810.3892/ol.2016.4698495024627446367Search in Google Scholar

17. J. Liang, F. Xu, Y. Z. Zhang., S. Huang, X. Y. Zang, X. Zhao, L. Zhang, M. Y. Shang, D. H. Yang, X. Wang and S. Q. Cai, The profiling and identification of the absorbed constituents and metabolites of Paeoniae radix rubra decoction in rat plasma and urine by the HPLC-DAD-ESI-IT-TOF-MS(n) technique: a novel strategy for the systematic screening and identification of absorbed constituents and metabolites from traditional Chinese medicines, J. Pharm. Biomed. Anal.83 (2013) 108–121; https://doi.org/10.1016/j.jpba.2013.04.02910.1016/j.jpba.2013.04.02923727363Search in Google Scholar

18. H. Wu, W. Li, T. Wang, Y. Shu and P. Liu, Paeoniflorin suppress NF-kappaB activation through modulation of I kappaB alpha and enhances 5-fluorouracil-induced apoptosis in human gastric carcinoma cells, Biomed. Pharmacother.62 (2008) 659–666; https://doi.org/10.1016/j.biopha.2008.08.00210.1016/j.biopha.2008.08.00218809274Search in Google Scholar

19. S. Fang, W. Zhu, Y. Zhang, Y. Shu and P. Liu, Paeoniflorin modulates multidrug resistance of a human gastric cancer cell line via the inhibition of NF-κB activation, Mol. Med. Rep.5 (2012) 351–356; https://doi.org/10.3892/mmr.2011.65210.3892/mmr.2011.65222051979Search in Google Scholar

20. H. Wang, H. Zhou, C. X. Wang, Y. S. Li, H. Y. Xie, J. D. Luo and Y. Zhou, Paeoniflorin inhibits growth of human colorectal carcinoma HT 29 cells in vitro and in vivo, Food. Chem. Toxicol.50 (2012) 1560–1567; https://doi.org/10.1016/j.fct.2012.01.03510.1016/j.fct.2012.01.035Search in Google Scholar

21. Z. D. Ge, A. W. Zhou, B. Wang, Y. X. Shen, C. H. Ding, A. P. Zhang, W. Wei and S. Y. Xu, Immunoregulatory effects of total glucosides of Paeony (TGP), Paeoniflorin (PF) and TGP removed PF on adjuvant arthritic rats, Chin. Pharmacol. Bull. 11 (1995) 303–305; https://doi.org/10.3321/j.issn:1001-1978.1995.04.012Search in Google Scholar

22. Y. L. Zhu, L. Y. Wang, J. X. Wang, C. Wang, C. L. Wang, D. P. Zhao, Z. C. Wang and J. J. Zhang, Protective effects of paeoniflorin and albiflorin on chemotherapy-induced myelosuppression in mice, Chin. J. Nat. Med.14 (2016) 599–606; https://doi.org/10.1016/S1875-5364(16)30070-X10.1016/S1875-5364(16)30070-XSearch in Google Scholar

23. S. Goldar, M. S. Khaniani, S. M. Derakhshan and B. Baradaran, Molecular mechanisms of apoptosis and roles in cancer development and treatment, Asian Pac. J. Cancer. Prev.16 (2015) 2129–2144; https://doi.org/10.7314/APJCP.2015.16.6.212910.7314/APJCP.2015.16.6.212925824729Search in Google Scholar

24. Z. Jin and W. S. El-Deiry, Overview of cell death signaling pathways, Cancer Biol. Ther.4 (2005) 139–163; https://doi.org/10.4161/cbt.4.2.150810.4161/cbt.4.2.150815725726Search in Google Scholar

25. S. Wang and W. Liu, Paeoniflorin inhibits proliferation and promotes apoptosis of multiple myeloma cells via its effects on microRNA-29b and matrix metalloproteinase-2, Mol. Med. Rep.14 (2016) 2143–2149; https://doi.org/10.3892/mmr.2016.549810.3892/mmr.2016.549827430753Search in Google Scholar

26. N. Yang, H. Cui, F. Han, L. Zhang, T. Huang, Y. Zhou and J. Zhou, Paeoniflorin inhibits human pancreatic cancer cell apoptosis via suppression of MMP-9 and ERK signaling, Oncol. Lett.12 (2016) 1471–1476; https://doi.org/10.3892/ol.2016.476110.3892/ol.2016.4761495081827446455Search in Google Scholar

27. Z. Zhou, S. Wang, C. Song and Z. Hu, Paeoniflorin prevents hypoxia-induced epithelial-mesenchymal transition in human breast cancer cells, Onco. Targets Ther.9 (2016) 2511–2518; https://doi.org/10.2147/OTT.S10242210.2147/OTT.S102422485423427175085Search in Google Scholar

28. S. Hu, W. Sun, W. Wei, D. Wang, J. Jin, J. Wu, J. Chen, H. Wu and Q. Wang, Involvement of the prostaglandin E receptor EP2 in paeoniflorin-induced human hepatoma cell apoptosis, Anticancer Drugs.24 (2013) 140–149; https://doi.org/10.1097/CAD.0b013e32835a4dac10.1097/CAD.0b013e32835a4dac23069790Search in Google Scholar

29. H. Yu and R. Jove, The STATs of cancer--new molecular targets come of age, Nat. Rev. Cancer.4 (2004) 97–105; https://doi.org/10.1038/nrc127510.1038/nrc127514964307Search in Google Scholar

30. P. K. Epling-Burnette, J. H. Liu, R. Catlett-Falcone, J. Turkson, M. Oshiro, R. Kothapalli, Y. Li, J. M. Wang, H. F.Yang-Yen, J. Karras, R. Jove and T. P. Jr. Loughran, Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression, J. Clin. Invest.107 (2001) 351–362; https://doi.org/10.1172/JCI994010.1172/JCI994019918811160159Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo